271 related articles for article (PubMed ID: 25827155)
1. Inflammation in acute CNS injury: a focus on the role of substance P.
Corrigan F; Vink R; Turner RJ
Br J Pharmacol; 2016 Feb; 173(4):703-15. PubMed ID: 25827155
[TBL] [Abstract][Full Text] [Related]
2. The Role of Neurogenic Inflammation in Blood-Brain Barrier Disruption and Development of Cerebral Oedema Following Acute Central Nervous System (CNS) Injury.
Sorby-Adams AJ; Marcoionni AM; Dempsey ER; Woenig JA; Turner RJ
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28817088
[TBL] [Abstract][Full Text] [Related]
3. NK1 receptor blockade is ineffective in improving outcome following a balloon compression model of spinal cord injury.
Leonard AV; Thornton E; Vink R
PLoS One; 2014; 9(5):e98364. PubMed ID: 24859234
[TBL] [Abstract][Full Text] [Related]
4. Substance P in traumatic brain injury.
Donkin JJ; Turner RJ; Hassan I; Vink R
Prog Brain Res; 2007; 161():97-109. PubMed ID: 17618972
[TBL] [Abstract][Full Text] [Related]
5. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
6. The potential for substance P antagonists as anti-cancer agents in brain tumours.
Harford-Wright E; Lewis KM; Vink R
Recent Pat CNS Drug Discov; 2013 Apr; 8(1):13-23. PubMed ID: 23477306
[TBL] [Abstract][Full Text] [Related]
7. Substance P antagonists as a therapeutic approach to improving outcome following traumatic brain injury.
Vink R; van den Heuvel C
Neurotherapeutics; 2010 Jan; 7(1):74-80. PubMed ID: 20129499
[TBL] [Abstract][Full Text] [Related]
8. Kinin receptor antagonists as potential neuroprotective agents in central nervous system injury.
Thornton E; Ziebell JM; Leonard AV; Vink R
Molecules; 2010 Sep; 15(9):6598-618. PubMed ID: 20877247
[TBL] [Abstract][Full Text] [Related]
9. Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation.
Corrigan F; Mander KA; Leonard AV; Vink R
J Neuroinflammation; 2016 Oct; 13(1):264. PubMed ID: 27724914
[TBL] [Abstract][Full Text] [Related]
10. Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Harford-Wright E; Lewis KM; Ghabriel MN; Vink R
PLoS One; 2014; 9(5):e97002. PubMed ID: 24818961
[TBL] [Abstract][Full Text] [Related]
11. Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours.
Lewis KM; Harford-Wright E; Vink R; Ghabriel MN
J Neuroimmunol; 2012 Sep; 250(1-2):59-65. PubMed ID: 22722013
[TBL] [Abstract][Full Text] [Related]
12. A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke.
Turner RJ; Helps SC; Thornton E; Vink R
Brain Res; 2011 Jun; 1393():84-90. PubMed ID: 21466790
[TBL] [Abstract][Full Text] [Related]
13. Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury.
Donkin JJ; Nimmo AJ; Cernak I; Blumbergs PC; Vink R
J Cereb Blood Flow Metab; 2009 Aug; 29(8):1388-98. PubMed ID: 19436311
[TBL] [Abstract][Full Text] [Related]
14. Substance P-induced inflammatory responses in guinea-pig skin: the effect of specific NK1 receptor antagonists and the role of endogenous mediators.
Walsh DT; Weg VB; Williams TJ; Nourshargh S
Br J Pharmacol; 1995 Apr; 114(7):1343-50. PubMed ID: 7541689
[TBL] [Abstract][Full Text] [Related]
15. Substance P antagonists as a novel intervention for brain edema and raised intracranial pressure.
Gabrielian L; Helps SC; Thornton E; Turner RJ; Leonard AV; Vink R
Acta Neurochir Suppl; 2013; 118():201-4. PubMed ID: 23564132
[TBL] [Abstract][Full Text] [Related]
16. Identification of an Intravenous Injectable NK1 Receptor Antagonist for Use in Traumatic Brain Injury.
Vink R; Nimmo A
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542509
[TBL] [Abstract][Full Text] [Related]
17. Advancing drug therapy for brain tumours: a current review of the pro-inflammatory peptide Substance P and its antagonists as anti-cancer agents.
Mander K; Harford-Wright E; Lewis KM; Vink R
Recent Pat CNS Drug Discov; 2014; 9(2):110-21. PubMed ID: 25386916
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of neurogenic inflammation as a novel treatment for ischemic stroke.
Turner R; Vink R
Timely Top Med Cardiovasc Dis; 2007 Oct; 11():E24. PubMed ID: 18297137
[TBL] [Abstract][Full Text] [Related]
19. The Role of Substance P Within Traumatic Brain Injury and Implications for Therapy.
Safwat A; Helmy A; Gupta A
J Neurotrauma; 2023 Aug; 40(15-16):1567-1583. PubMed ID: 37132595
[TBL] [Abstract][Full Text] [Related]
20. Substance P and its Inhibition in Ocular Inflammation.
Bignami F; Rama P; Ferrari G
Curr Drug Targets; 2016; 17(11):1265-74. PubMed ID: 26477461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
